Eosinophilic diseases encompass a spectrum of rare, complex conditions—from gastrointestinal manifestations including eosinophilic oesophagitis (EoE), eosinophilic gastritis (EG), and eosinophilic duodenitis (EoD), to systemic vasculitic and myeloproliferative disorders such as eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES). Each presents unique diagnostic, management, and treatment optimisation challenges that reflect the complexity of eosinophilic disease across diverse patient populations. With expanding therapeutic options and growing recognition of disease phenotypes and heterogeneity within this rare group of diseases, robust real-world evidence is essential for understanding disease burden, validating treatment approaches, supporting healthcare access decisions, and ensuring that patient voices are central to research and innovation.
Adelphi Real World’s Eosinophilic Disease Specific Programmes (DSPs) are purpose-designed to deliver this evidence.
Translating Eosinophilic Disease Evidence Into Action
Our Eosinophilic Disease DSPs engage specialist clinicians and patients to generate intelligence grounded in authentic clinical experience:
Condition Recognition & Diagnostic Pathways
Understand how specialists diagnose and recognise eosinophilic diseases—capturing diagnostic approaches, diagnostic delays, specialist referral patterns, and disease identification in routine clinical practice.
Treatment Selection & Therapeutic Strategies
Benchmark real-world therapy patterns: how clinicians choose and optimise treatments—from corticosteroids through advanced targeted therapies—across eosinophilic conditions, including treatment sequencing and combination approaches.
Disease Burden & Symptom Impact
Explore condition-specific impacts: symptom severity, functional limitations, disease progression, gastrointestinal or systemic manifestations, psychological burden, work productivity, and quality-of-life consequences for patients.
Treatment Outcomes & Effectiveness
Track real-world effectiveness: symptom control, disease remission, functional improvement, biomarker improvement, treatment durability, and patient satisfaction across diverse patient populations and healthcare settings.
Unmet Needs & Care Gaps
Identify areas where current management is inadequate, diagnostic delays, treatment barriers, specialist access challenges, and opportunities for therapeutic innovation in eosinophilic disease.
Eosinophilic Disease Specific Programmes (DSP) Portfolio
Why Choose Adelphi for Eosinophilic Disease Research?
Eosinophilic Disease Specialisation
Deep expertise across gastrointestinal eosinophilic conditions (EoE) and systemic eosinophilic disorders (EGPA, HES).
Authentic Specialist Clinician Networks
Access to gastroenterologists, pulmonologists, rheumatologists, immunologists, allergy specialists, and internists across diverse care settings.
Patient-Centred Approach
Evidence prioritising the lived experience of patients with eosinophilic diseases, including functional, psychological, and quality-of-life impacts.
Comprehensive Condition Coverage
Intelligence spanning gastrointestinal and systemic eosinophilic diseases across diverse patient journeys and disease trajectories.
Rigorous Methodology
Robust data collection capturing both clinical outcomes and patient-reported experiences specific to eosinophilic conditions.
Strategic Intelligence
Evidence supporting clinical development, rare disease positioning, reimbursement, and specialist healthcare provider engagement.
Publications
We publish widely at both conferences and in journals. Recent publications include:
EGPA posters
| Le TT, Smith SG, Hennessy F, Carter OT, Lucas J, Kabir A, Salmon P, Mu G, Wechsler ME. Variation of clinical characteristics and disease burden in subgroups of patients with eosinophilic granulomatosis with polyangiitis (EGPA). Poster presented at: ATS; 2026 May 15-20; Orlando, FL |
| Ding B, Spiera R, Dolin P, Westerink L, Edmonds C, Kielar D, Carter OT, Pennant T, Hennessy F, Chen SY. EGPA disease burden in Europe and US: evidence from real-world clinical practice. Poster presented at: ERS; 2025 Sep-Oct 27-1; Amsterdam, The Netherlands |
| Chen SY, Spiera R, Dolin P, Ding B, Shavit A, Rowell J, Edmonds C, Kielar D, Mascia D, Pennant T, Hennessy F. Real-world treatment patterns in patients with eosinophilic granulomatosis with polyangiitis (EGPA). Poster presented at: ATS; 2025 May 18-21; San Diego, CA |
| Spiera R, Dolin P, Shavit A, Rowell J, Edmonds C, Persson J, Kielar D, Mascia D, Pennant T, Hennessy F, Chen SY. The impact of eosinophilic granulomatosis with polyangiitis on the health-related quality of life of patients and their ability to work: evidence from a real-world survey in clinical practice. Poster presented at: ACR; 2024 Nov 14-19; Washington, DC |
HES posters
| . Patient perspectives on disease burden and management of hypereosinophilic syndrome in Europe and the US: evidence from a real-world survey in clinical practice. Poster presented at: IES; 2025 Jul 7-11; Paris, France |
| . Patient perspectives on disease burden and management of hypereosinophilic syndrome in Europe and the US: evidence from a real-world survey in clinical practice. Abstract accepted at: EHA; 2025 Jun 12-15; Milan, Italy |
| Schwaab J, Dolin P, Jain P, Rowell J, Edmonds C, Persson J, Mascia D, Pennant T, Hennessy F, Chen SY. Health-related quality of life, work productivity and activity impairment, and fatigue in patients with idiopathic or lymphocytic hypereosinophilic syndrome: a real-world survey. Poster presented at: ASH; 2024 Dec 7-10; San Diego, CA |
| Dolin P, Jain P, Edmonds C, Flynn P, Mascia D, Pennant T, Chen SY. A real-word survey of disease burden among patients with hypereosinophilic syndrome. Poster presented at: ACAAI; 2024 Oct 24-28; Boston, MA |
| Dolin P, Jain P, Rowell J, Edmonds C, Eudicone J, Flynn P, Mascia D, Siddall J, Pennant T, Robinson J, Chen SY. Patient journey to diagnosis and treatment of hypereosinophilic syndrome in Europe and the United States: evidence from a real-world survey in clinical practice. Poster presented at: DGRh; 2024 Sep 18-21; Dusseldorf, Germany |
| Dolin P, Jain P, Rowell J, Edmonds C, Eudicone J, Flynn P, Mascia D, Siddall J, Pennant T, Robinson J, Chen SY. Patient journey to diagnosis and treatment of hypereosinophilic syndrome in Europe and the United States: evidence from a real-world survey in clinical practice. Poster presented at: EHA; 2024 Jun 13-16; Madrid, Spain |
EOE posters
| Biedermann L, Dave K, Zema C, Mascia D, Pennant T, Chang JW. Misdiagnosis is common on the path to eosinophilic esophagitis. Poster presented at: UEGW; 2024 Oct 12-15; Vienna, Austria |
| Chang JW, Ejzykowicz F, Zema CL, Mascia D, Pennant T, Higgins C, Biedermann L. Assessing the concordance between patients with eosinophilic esophagitis and their treating physicians: evidence from a real-world study. Poster presented at: ACG; 2024 Oct 25-30; Philadelphia, PA |
| Chang JW, Ejzykowicz F, Zema CL, Mascia D, Higgins C, Biedermann L. Unmet needs among patients with eosinophilic esophagitis despite biologic use. Poster presented at: ACG; 2024 Oct 25-30; Philadelphia, PA |
| Mascia D, Weatherby S, Mathew J, Pennant T, Robinson J, Biswas M. Unmet Treatment Needs in the Management of Patients with Eosinophilic Esophagitis: Insights from a Real-world Survey. Poster presented at: ISPOR US; 2024 May 5-8; Atlanta, GA |
| Xu X, Kwiatek J, Siddall J, Genofre E, Stirnadel-Farrant H, Katial R. Characterization of patients with eosinophilic esophagitis managed by gastroenterologists and allergists: real-world clinical practice evidence. Poster presented at: ACAAI; 2022 Nov 10-14; Louisville KY |
| Xu X, Kwiatek J, Siddall J, Genofre E, Stirnadel-Farrant H, Katial R. Patient-reported symptoms of eosinophilic esophagitis in the United States: evidence from real-world clinical practice. Poster presented at: ACAAI; 2022 Nov 10-14; Louisville KY |
| Xu X, Kwiatek J, Siddall J, Brailean A, Stirnadel-Farrant H, Earl L, Katial R. Physician-documented symptoms and treatment among patients with eosinophilic esophagitis in five European countries: evidence from real-world clinical practice. Poster presented at: UEGW; 2022 Oct 8-11; Vienna, Austria |
| Xu X, Kwiatek J, Siddall J, Brailean A, Stirnadel-Farrant H, Earl L, Katial R. Patient-reported symptoms of eosinophilic esophagitis in five European countries: evidence from real-world clinical practice. Poster presented at: UEGW; 2022 Oct 8-11; Vienna, Austria |
| Xu X, Kwiatek J, Siddall J, Genofre E, Stirnadel-Farrant H, Katial R. Physician-documented symptoms and treatment among patients with eosinophilic esophagitis in the United States: evidence from real-world clinical practice. Poster presented at: ACG; 2022 Oct 21-26; Charlotte, NC |
| Xu X, Kwiatek J, Siddall J, Genofre E, Stirnadel-Farrant H, Katial R. Disease burden and diagnosis pathways among patients with EoE in the United States: evidence from real-world clinical practice. Poster presented at: ACG; 2022 Oct 21-26; Charlotte, NC |
EOE manuscripts
| Schoepfer AM, Olsen S, Siddall J, McCann E, Kamat S, Borsos K, Khodzhayev A, Radwan A, Pela T, Jacob-Nara J, Tilton ST, Thomas RB. Burden of eosinophilic esophagitis in adult and adolescent patients: results from a real-world analysis. Dis Esophagus. 2025; 38(2): doaf024 |
Current Countries Respiratory DSPs Cover
Current Eosinophilic Disease DSPs Sample Size
Who We Collaborate With
We partner with pharmaceutical innovators, gastroenterology and immunology centres, specialist eosinophilic disease societies, patient advocacy organisations, and healthcare commissioners to advance eosinophilic disease research and improve outcomes for patients globally.
Ready to Partner?
- Schedule a Consultation: Meet with our eosinophilic disease specialists to explore how our real-world evidence supports your eosinophilic disease programmes.
- Learn About Our Approach: Interested in our clinician networks, global reach, condition expertise, or patient-centred methodology? Contact us for comprehensive information.
Eosinophilic diseases deserve research partners who understand their diagnostic complexity, specialist management challenges, and prioritise the authentic experiences of patients navigating these rare conditions.
Adelphi Real World brings specialist expertise, authentic practitioner and patient networks, and rigorous methodology grounded in eosinophilic disease realities.
Let’s collaborate to generate evidence that drives innovation and better outcomes for eosinophilic disease.
Contact us today using the form below.
Respiratory DSPs
Conferences Attending